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Summary
Background and Objective: A recent Cochrane review on pla-
cebo interventions for all kinds of conditions found that ‘physi-
cal placebos’ (which included sham acupuncture) were associ-
ated with larger effects over no-treatment control groups than 
‘pharmacological placebos’. We re-analyzed the data from this 
review to investigate whether effects associated with sham ac-
upuncture differed from those of other ‘physical placebos’. 
Methods: All trials included in the Cochrane review as investi-
gating ‘physical placebos’ were classified as investigating ei-
ther (sham) acupuncture or other physical placebos. The latter 
group was further subclassified into groups of similar interven-
tions. Data from the Cochrane review were re-entered into the 
RevMan 5 software for meta-analysis. The primary analysis 
was a random-effects analysis of trials reporting continuous 
outcomes of trials that used either sham acupuncture or other 
physical placebos. Results: Out of a total of 61 trials which re-
ported a continuous outcome measure, 19 compared sham ac-
upuncture and 42 compared other physical placebos with a no-
treatment control group. The trials re-analyzed were highly het-
erogeneous regarding patients, interventions and outcomes 
measured. The pooled standardized mean difference was –0.41 
(95% confidence interval –0.56, –0.24) between sham acupunc-
ture and no treatment and –0.26 (95% CI –0.37, –0.15) between 
other physical placebos and no treatment (p value for subgroup 
differences = 0.007). Significant differences were also observed 
between subgroups of other physical placebos. Conclusion: 
Due to the heterogeneity of the trials included and the indirect 
comparison our results must be interpreted with caution. Still, 
they suggest that sham acupuncture interventions might, on 
average, be associated with larger effects than pharmacological 
and other physical placebos.
Schlüsselwörter
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Zusammenfassung
Hintergrund und Fragestellung: In einem aktuellen Cochrane-
Review zu Placeboeffekten in klinischen Studien ergab sich, 
dass «physikalische Placebos» (inklusive Scheinakupunktur) 
mit größeren Effekten gegenüber unbehandelten Kontrollgrup-
pen assoziiert waren als «pharmakologische Placebos». Die 
Daten dieses Reviews wurden reanalysiert, um zu untersuchen, 
ob sich die mit Scheinakupunktur assoziierten Effekte von 
denen anderer «physikalischer Placebos» unterscheiden. Me-
thoden: Alle in den Cochrane-Review eingeschlossenen Stu-
dien mit «physikalischen Placebos» wurden in Studien mit 
Scheinakupunktur und Studien mit anderen physikalischen Pla-
cebos unterteilt. Die zweite Gruppe wurde weiter unterteilt in 
Gruppen ähnlicher Interventionen. Die Daten des Cochrane- 
Reviews wurden in die RevMan-5-Software eingegeben und 
ausgewertet. Als Hauptauswertung wurde eine Random- 
Effects-Analyse der Studien mit Scheinakupunktur und anderen 
phy sikalischen Placebos mit kontinuierlichen Zielgrößen durch-
geführt. Ergebnisse: Von insgesamt 61 Studien mit einer 
kontinuierlichen Zielgröße verglichen 19 eine Scheinakupunk-
turintervention und 42 ein andere physikalische Placebointer-
vention mit Nichtbehandlung. Die Studien waren in hohem 
Maße heterogen bezüglich Patienten, Interventionen und Ziel-
kriterien. Die gepoolte standardisierte Mittelwertsdifferenz be-
trug –0,41 (95%-Konfidenzintervall: –0,56; –0,24) für den Ver-
gleich Scheinakupunktur versus Nichtbehandlung und –0,26 
(–0,37; –0,15) für den Vergleich andere physikalische Placebos 
versus Nichtbehandlung (p-Wert für Unterschiede zwischen 
den Subgruppen = 0,007). Signifikante Unterschiede traten 
auch zwischen den weiteren Subgruppen physikalischer Place-
bos auf. Schlussfolgerung: Aufgrund des indirekten Vergleichs 
und der ausgeprägten klinischen Heterogenität der Studien 
müssen die Ergebnisse mit Zurückhaltung interpretiert werden. 
Sie deuten aber darauf hin, dass Scheinakupunkturinterven-
tionen im Durchschnitt mit größeren Effekten einhergehen als 
pharmakologische und andere physikalische Placebos.
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Table 1. Acupunc-
ture studies included 
in the Cochrane 
 review [8]
Table 2. Additional 
analyses
randomized trials on any condition which had both a placebo or sham 
group and a no-treatment group (or more exactly, a group which did not 
receive any intervention that was not also received in the sham group). 
In their main analysis Hrobjartsson and Gøtzsche pooled all trials with 
continuous or dichotomous outcomes regardless of conditions, interven-
tions and outcomes assessed. In addition, they performed a large number 
of subgroup analyses to investigate whether these factors as well as de-
sign features had an impact on outcomes. Our re-analyses are based on 
their comparison 7.6 which included 61 trials using ‘physical placebos’ 
(other categories were psychological and pharmacological placebos) and 
reporting data for a continuous outcome measure. Furthermore, we also 
re-analyzed comparison 7.2 which included 11 additional trials reporting 
dichotomous outcomes. One of us went through the table of studies in-
cluded in the review and classified the interventions provided in the trials 
into acupuncture studies and other studies. The latter were then catego-
rized further into clinically more homogeneous subgroups of at least 
4 trials each. Another reviewer then re-entered the outcome data ex-
tracted and reported by Hrobjartsson and Gøtzsche into the Cochrane 
Collaboration’s Review Manager Software 5 (RevMan 5). The third re-
viewer checked all data entries against those in the original review. Like 
Hrobjartsson and Gøtzsche we calculated SMDs (difference between the 
means of the groups compared, divided by the pooled standard devia-
tion) for trials reporting continuous outcome measures (with negative 
values indicating superiority of sham over no treatment) and risk ratios 
for dichotomous outcomes (with values <1 indicating superiority of sham 
over no treatment). We then performed random-effects meta-analyses 
using the inverse variance method. To investigate statistical heterogene-
ity, RevMan 5 uses Tau2, Chi2 and I2. We considered I2 values between 
30% and 60% as indicating moderate heterogeneity and higher values as 
indicating substantial heterogeneity. Subgroup comparisons were per-
formed using the method implemented in RevMan 5 [9]. It has to be 
taken into account that p values for subgroup differences can be calcu-
lated only for fixed- effects estimates by this software. The primary analy-
sis was acupuncture trials versus all other trials with continuous out-
comes. In addition, we performed an analysis for dichotomous outcome 
measures as well as subgroup and sensitivity analyses to test the robust-
ness of the results.
Results
The Cochrane review included a total of 19 (sham) acupunc-
ture trials which reported continuous outcomes [10–28] and 5 
acupuncture trials which reported a dichotomous outcome 
[29–33]. These 24 acupuncture studies addressed a great vari-
ety of conditions and interventions (table 1). One of the stud-
ies used as sham treatment an intervention we consider as 
true acupuncture: in the sham group patients with postopera-
tive pain received acupuncture at point ST 36, whereas in the 
patients of the experimental group the needles were addition-
ally also stimulated electrically [20]. As an exclusion of that 
study did not have a major impact on the pooled effect esti-
mate (table 2) we included it in our analyses to keep the data 
set as similar as possible to the original one by Hrobjartsson 
and Gøtzsche. 
Out of the 42 studies using ‘physical placebos’ 11 trials in-
vestigated either acupressure or laser acupuncture, 10 trials 
were on transcutaneous electrical nerve stimulation, 7 trials 
investigated electrotherapy, ultrasound or a physiotherapeu-
tic intervention, 4 trials were on osteopathy or chiropractic 
Introduction
Placebo-controlled trials are a crucial tool to investigate 
whether the clinical effects of an intervention are truly due to 
the ‘specific’ or ‘characteristic’ elements of an intervention [1, 
2]. In the case of complex interventions it is often not easy to 
define which aspects are ‘specific’ or ‘characteristic’ and which 
are ‘non-specific’ or ‘incidental’. As a consequence, it is diffi-
cult to devise an adequate placebo or sham intervention 
which is both inert and indistinguishable from the true inter-
vention. Furthermore, even if inert on a physiological level, 
some placebos might be more powerful than others on a sym-
bolical level. It has been argued both that sham acupuncture 
interventions might be particularly potent placebos [3] and 
that most sham acupuncture interventions are physiologically 
active [4]. If sham acupuncture (and other complex sham in-
terventions) – for any of the two reasons mentioned or a com-
bination of both reasons – would indeed be associated with 
larger improvements than, for example, a pharmacological 
placebo this could make it more difficult to show ‘specific’ ef-
fects for acupuncture and other complex interventions than 
for drugs.
The most straightforward way to investigate whether sham 
acupuncture is associated with larger effects than, for exam-
ple, a medical placebo would be in randomized trials includ-
ing both these interventions. Such trials are extremely rare, 
but the few available findings indeed suggest that sham acu-
puncture and other complex interventions are associated with 
larger effects than medical placebos [3, 5]. Another, albeit 
methodologically weaker, possibility is to compare differences 
between sham acupuncture interventions and no-treatment 
control groups in acupuncture trials with those of (other) pla-
cebos and no-treatment control groups in other trials. Hrob-
jartsson and Gøtzsche have repeatedly reviewed all available 
trials including both a placebo or sham and a no-treatment 
group for any condition [6–8]. The latest update of their Co-
chrane review includes a total of 234 trials. In a pre-planned 
subgroup analysis they found that studies using ‘physical pla-
cebos’ (including sham acupuncture) reported larger ‘placebo 
effects’ (standardized mean difference (SMD) –0.31; 95% 
confidence interval (CI) –0.41, –0.22) than studies using ‘phar-
macological placebos’ (SMD –0.10; 95% CI –0.20, –0.01) [8]. 
If acupuncture was indeed a symbolically powerful interven-
tion and/or if sham acupuncture interventions were not physi-
ologically inert, sham acupuncture interventions could have 
larger effects over no-treatment controls than other ‘physical 
placebos.’ We re-analyzed the data by Hrobjartsson and 
Gøtzsche to investigate this hypothesis. 
Methods
Methods and findings of the review by Hrobjartsson and Gøtzsche are 
described in detail in the original publication [8]. Their review included 
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First author, year [ref] N* Condition Sham (number of sessions)
Trials with continuous outcome
Allen, 1998 [11]  22 depression needling at non-indicated points (12)
Allen, 2006 [10]  89 depression needling at non-indicated points (12)
Brinkhaus, 2006 [12] 144 chronic low back pain needling outside of points (12)
Cabrini, 2006 [13]  32 bronchoscopy needling outside of points (1)
Foster, 2007 [14] 217 osteaoarthritis of the knee placebo needles at correct points (6)
Helms, 1987 [15]  22 primary dysmenorrhea needling outside of points (9)
Kaptchuk, 2008 [16] 175 irritable bowel syndrome placebo needles outside of points (6)
Karst, 2007 [17]  29 tooth extraction placebo needles outside of points (1)
Kotani, 2001 [18]  47 pain at abdominal scares needling outside of points (20)
Leibing, 2002 [19]  79 chronic low back pain needling outside of points (20)
Lin, 2002 [20]  50 postoperative pain needling of ST 36 without electro-stimulation (1)
Linde, 2005 [21] 157 migraine needling outside of points (12)
Medici, 2002 [22]  41 asthma needling outside of points (16)
Melchart, 2005 [23] 120 tension-type headache needling outside of points (12)
Röschke, 2000 [24]  48 depression needling outside of points (12)
Rösler, 2003 [25]  27 transesoph. echocardiogr. needling outside of points (1)
Shen, 2000 [26]  67 chemotherapy-ind. nausea needling outside of points (5)
Tremeau, 1992 [27]  64 cervical maturation needling outside of points (3)
Witt, 2005 [28] 140 osteoarthritis of the knee needling outside of points (12)
Trials with dichotomous outcomes
Aune, 2002 [29]  40 recurrent urinary tract inf. needling outside of points (1)
Dundee, 1986 [30]  50 postoperative nausea needling outside of points (8)
Fanti, 2003 [31]  20 coloscopy needling outside of points (1)
Molsberger, 2002 [32] 111 chronic low back pain needling outside of points (12)
Scharf, 2006 [33] 681 osteoarthritis of the knee needling outside of points (10 to 15)
*Sum of participants in sham and no-treatment group.
Table 1. Acupunc-
ture studies included 
in the Cochrane 
 review [8]
Analysis SMD (95% CI) random effects I2/p value
Trials with continous outcome measures
Acupuncture trials without Lin, 2002 (n = 18) –0.40 (–0.56, – 0.25) 51%
Acupuncture trials without ART trials (n = 15) –0.30 (–0.46, –0.13) 33%
Intervention subgroup analysis
– Acupressure and laser acupuncture trials (n = 11)
– Transcutaneous nerve stimulation trials (n = 10)
– Physio-, electro- and ultrasound therapy trials (n = 7)
– Chiropractic and osteopathy trials (n = 4)
– Other trials (n = 10)
Test for subgroup differences
–0.20 (–0.35, –0.04)
–0.11 (–0.24, 0.02)
–0.52 (–0.74, –0.30)
–0.40 (–0.88, 0.08)
–0.26 (–0.66, 0.14)
 0%
 0%
 0%
 0%
72%
0.01
Sham type analysis
– Sham interventions with skin penetration (n = 16)
– Sham interventions without skin penetration (n = 3)
Test for subgroup differences
–0.43 (–0.59, .0.28)
–0.37 (–0.79, 0.04)
39%
71%
0.05
RR (95% CI) random effects
Trials with dichotomous outcome measures
Main analysis dichotomous outcome measures
– Acupuncture trials (n = 5)
– Other trials (n = 6)
Test for subgroup differences
0.86 (0.67, 1.11)
0.90 (0.89, 1.00)
68%
 0%
0,001
Acupuncture trials without Scharf, 2006 (n = 4) 0.98 (0.81, 1.19)  5%
Table 2. Additional 
analyses
randomized trials on any condition which had both a placebo or sham 
group and a no-treatment group (or more exactly, a group which did not 
receive any intervention that was not also received in the sham group). 
In their main analysis Hrobjartsson and Gøtzsche pooled all trials with 
continuous or dichotomous outcomes regardless of conditions, interven-
tions and outcomes assessed. In addition, they performed a large number 
of subgroup analyses to investigate whether these factors as well as de-
sign features had an impact on outcomes. Our re-analyses are based on 
their comparison 7.6 which included 61 trials using ‘physical placebos’ 
(other categories were psychological and pharmacological placebos) and 
reporting data for a continuous outcome measure. Furthermore, we also 
re-analyzed comparison 7.2 which included 11 additional trials reporting 
dichotomous outcomes. One of us went through the table of studies in-
cluded in the review and classified the interventions provided in the trials 
into acupuncture studies and other studies. The latter were then catego-
rized further into clinically more homogeneous subgroups of at least 
4 trials each. Another reviewer then re-entered the outcome data ex-
tracted and reported by Hrobjartsson and Gøtzsche into the Cochrane 
Collaboration’s Review Manager Software 5 (RevMan 5). The third re-
viewer checked all data entries against those in the original review. Like 
Hrobjartsson and Gøtzsche we calculated SMDs (difference between the 
means of the groups compared, divided by the pooled standard devia-
tion) for trials reporting continuous outcome measures (with negative 
values indicating superiority of sham over no treatment) and risk ratios 
for dichotomous outcomes (with values <1 indicating superiority of sham 
over no treatment). We then performed random-effects meta-analyses 
using the inverse variance method. To investigate statistical heterogene-
ity, RevMan 5 uses Tau2, Chi2 and I2. We considered I2 values between 
30% and 60% as indicating moderate heterogeneity and higher values as 
indicating substantial heterogeneity. Subgroup comparisons were per-
formed using the method implemented in RevMan 5 [9]. It has to be 
taken into account that p values for subgroup differences can be calcu-
lated only for fixed- effects estimates by this software. The primary analy-
sis was acupuncture trials versus all other trials with continuous out-
comes. In addition, we performed an analysis for dichotomous outcome 
measures as well as subgroup and sensitivity analyses to test the robust-
ness of the results.
Results
The Cochrane review included a total of 19 (sham) acupunc-
ture trials which reported continuous outcomes [10–28] and 5 
acupuncture trials which reported a dichotomous outcome 
[29–33]. These 24 acupuncture studies addressed a great vari-
ety of conditions and interventions (table 1). One of the stud-
ies used as sham treatment an intervention we consider as 
true acupuncture: in the sham group patients with postopera-
tive pain received acupuncture at point ST 36, whereas in the 
patients of the experimental group the needles were addition-
ally also stimulated electrically [20]. As an exclusion of that 
study did not have a major impact on the pooled effect esti-
mate (table 2) we included it in our analyses to keep the data 
set as similar as possible to the original one by Hrobjartsson 
and Gøtzsche. 
Out of the 42 studies using ‘physical placebos’ 11 trials in-
vestigated either acupressure or laser acupuncture, 10 trials 
were on transcutaneous electrical nerve stimulation, 7 trials 
investigated electrotherapy, ultrasound or a physiotherapeu-
tic intervention, 4 trials were on osteopathy or chiropractic 
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moderate for both subgroups of trials with I2 being 49% and 
38%, respectively. According to Hrobjartsson and Gøtzsche, 
a series of 4 recent large acupuncture trials from Germany 
had considerable impact on the overall estimate. When these 
4 trials [i.e. 12, 21, 23, 28] contributing to the analysis of con-
tinuous outcomes were excluded, the pooled effect estimate 
was reduced to –0.30 (95% CI –0.46, –0.13) and no longer dif-
fered significantly from that for non-acupuncture studies.
When we analyzed separately the different categories of 
‘physical placebos’ other than sham acupuncture, SMDs be-
tween subgroups differed significantly (test for subgroup dif-
ferences Chi2 = 12.90, p = 0.01; see table 2). The pooled SMD 
over no-treatment controls for placebos for electrotherapy, 
ultrasound or a physiotherapeutic intervention was slightly 
larger (–0.52) than for sham acupuncture (p = 0.44). The 
pooled random-effects relative risk (of a negative outcome) of 
the 5 studies which reported a dichotomous outcome measure 
for the comparison between the sham and the no-treatment 
group was 0.86 (95% CI 0.67, 1.11) for acupuncture studies 
and 0.94 (95% CI 0.89, 1.00) for other studies, confirming a 
larger effect of sham acupuncture (p value for differences be-
tween subgroups based on fixed-effects analyses = 0.001). 
When the recent large German trial [33] was excluded from 
this analysis, the difference was non-significant.
Discussion
In our re-analysis of data from the Cochrane review by Hrob-
jartsson and Gøtzsche on placebo interventions for all kinds 
of conditions [8] sham acupuncture interventions were, on av-
erage, associated with larger effects over no-treatment control 
groups than were other ‘physical placebos.’ However, if the 
group of other ‘physical placebos’ was further subdivided 
there were also significant differences between subgroups. 
Our results have to be interpreted with great caution. They 
are based on a re-analysis of a subgroup analysis from Hrob-
jartsson and Gøtzsche [8] with an indirect comparison of acu-
puncture and other trials. The trials included form an ex-
tremely heterogeneous sample and factors other than the 
sham interventions might have differed between the groups of 
trials compared. For example, it seems likely that effects of 
sham interventions vary between different conditions. Com-
parisons of sham acupuncture or other physical placebos and 
no-treatment groups cannot be blinded and many studies 
have measured subjective patient-rated endpoints. Further-
more, the extent of co-interventions in both sham or placebo 
trials using sham acupuncture and –0.26 (95% CI –0.37, –0.15) 
for other studies with ‘physical placebos’ (test for subgroup 
differences Chi2 = 7.37, p = 0.007; fig. 1). Heterogeneity was 
manipulations, and 10 trials were on various other therapies. 
The pooled random-effects SMD between sham interventions 
and no-treatment groups was –0.41 (95% CI –0.56, –0.26) for 
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Study or Subgroup
1.1.1 Acupuncture
Allen 1998
Allen 2006
Brinkhaus 2006
Cabrini 2006
Foster 2007
Helms 1987
Kaptchuk 2008
Karst 2007
Kotani 2001
Leibing 2002
Lin 2002
Linde 2005
Medici 2002
Melchart 2005
Röschke 2000
Rösler 2003
Shen 2000
Tremeau 1992
Witt 2005
Subtotal (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 35.13, df = 18 (P = 0.009); I² = 49%
Test for overall effect: Z = 5.31 (P < 0.00001)
1.1.2 Other
Alfano 2001
Benedetti 1997
Chenard 1991
Conn 1986
Coyne 1995
Defrin 2005
Dibble 2007
Erdogmus 2007
Foster 1994
Hargreaves 1989
Hashish 1986
Hashish 1988
Hong 1993
Hruby 2006
Hyland 2006
Kober 2002
Kokol 2005
Lander 1993
Licciardone 2003
Limoges 2004
Matros 2006
Moffet 1996
Morton 1993
Nawrocki 1997
O'Brien 1996
Robinson 2001
Roscoe 2002
Roscoe 2005
Sanders 1990
Sprott 1993
Stabholz 1991
Straub 2001
Sumaya 2001
Theroux 1993
Tritrakarn 2000
Tsay 2003
Tsay 2004
Wang 1997
Weingärtner 1971
Werntoft 2001
Woods 2005
Yates 1998
Subtotal (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 66.46, df = 41 (P = 0.007); I² = 38%
Test for overall effect: Z = 4.50 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 108.97, df = 60 (P = 0.0001); I² = 45%
Test for overall effect: Z = 6.64 (P < 0.00001)
Test for subgroup differences: Chi² = 7.38, df = 1 (P = 0.007), I² = 86.5%
Mean
-2.9
12
-23.6
61.7
6.5
103
-4.3
45.21
15
3.2
30.2
-2.2
-0.2
10.8
23
5.92
40.7
-0.89
35.8
6.2
0.26
29
28.2
0.73
7.3
3.13
-27.4
3.2
4.5
16
42
-1.09
1.23
6
66.7
9.5
28.5
2.46
2.27
76
24.04
22.11
9.5
6.7
3.85
5.9
2.4
2.03
7.9
1.4
-5.85
15.4
3.2
49
9.23
4.7
10.7
1.06
5.9
1.24
-1.43
SD
7.9
9.6
31
24
4.8
91
1.4
10.82
4.5
1.8
14.4
2.7
0.33
8.3
16.2
3.41
12.35
1.27
16.2
2.8
0.06
19
18.4
0.67
0.8
2.9
19.7
2.8
2.5
11.7
25
0.18
2.05
0.9
10
10.5
29.3
1.68
1.02
36.3
18.56
16.38
6
5.6
3.48
5.2
1.28
0.42
3
0.5
0.31
2.72
0.67
16
4.36
1.51
7.3
1.29
2.4
1.26
2.53
Total
11
45
70
16
112
11
88
19
23
40
25
76
23
57
24
13
33
39
73
798
24
106
12
13
21
9
49
40
15
25
25
25
16
49
10
20
16
172
19
30
23
22
13
40
53
13
27
31
6
10
10
5
10
17
41
32
35
25
15
20
19
7
1170
1968
Mean
-6.1
19
-6.9
66.6
6.78
79
-3.8
56.5
18
4.3
38.1
-0.8
-0.1
16.3
26
6
43.7
-1.08
49.6
6.6
0.27
30
44.4
0.64
7.6
3.5
-20.3
4.6
4.9
30
60
-1.02
0.86
6.2
64.4
7.3
32.3
3.54
2.23
72
34.56
24.53
17
7.5
4.25
6.6
2.8
2.08
7.4
1.8
-6.01
14.9
2.88
61
9.56
5.71
13.4
1.2
6.5
1.48
0.71
SD
10.9
9.6
22
28
4.5
99
1
9.1
6
1.9
16
2.2
0.31
7.4
16
2.98
11.31
1.38
16.3
2.7
0.06
19
15.7
0.67
0.65
3.1
19.7
2.2
2.4
18.9
23
0.07
1.5
0.9
13.3
6.6
33.4
2.67
1.01
28.3
23.2
16.38
4.8
5.14
3.74
3.64
1.32
0.28
3
0.6
0.69
1.8
0.62
17
4
1.82
5.8
1.56
2.2
1.12
1.44
Total
11
44
74
16
105
11
87
10
24
39
25
64
18
63
24
14
34
25
67
755
14
115
16
14
21
8
51
40
15
25
50
25
21
51
10
21
10
168
15
30
21
27
13
42
54
10
27
33
6
10
10
5
10
15
41
32
36
26
15
20
19
7
1199
1954
Weight
0.9%
2.2%
2.7%
1.2%
3.1%
0.9%
2.9%
1.0%
1.6%
2.1%
1.6%
2.7%
1.5%
2.5%
1.6%
1.1%
2.0%
1.9%
2.6%
36.2%
1.3%
3.1%
1.1%
1.0%
1.5%
0.8%
2.4%
2.1%
1.7%
1.9%
1.6%
1.3%
2.4%
0.9%
1.5%
1.0%
3.4%
1.3%
1.9%
1.5%
1.6%
1.1%
2.0%
2.5%
1.0%
1.7%
1.9%
0.6%
0.9%
0.8%
0.5%
0.9%
1.2%
2.1%
1.9%
2.0%
1.7%
1.2%
1.4%
1.4%
0.6%
63.8%
100.0%
IV, Random, 95% CI
0.32 [-0.52, 1.17]
-0.72 [-1.15, -0.29]
-0.62 [-0.96, -0.29]
-0.18 [-0.88, 0.51]
-0.06 [-0.33, 0.21]
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Fig. 1. Comparison 
of acupuncture trials 
and other trials using 
‘physical placebos’. 
Std. mean difference 
= standardized mean 
difference; SD = 
standard deviation; 
IV = inverse variance 
method, 95% CI = 
95% confidence in-
terval, df = degrees of 
freedom. Tau2 and I2 
are indicators of sta-
tistical heterogeneity.
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and no-treatment groups was highly variable. The results are 
also clearly affected by a series of 5 recent large German trials 
which all found relatively large effects of sham acupuncture 
over no-treatment groups [i.e. 12, 21, 23, 28, 33]. These Ger-
man trials have comparably high quality but if they are ex-
cluded, differences between sham acupuncture and other 
physical placebo are no longer significant. Therefore, further 
trials are required to investigate whether our findings are 
robust.
Despite these limitations, we believe that our results are a 
relevant contribution to the discussion on sham interventions 
in acupuncture research. There is accumulating evidence that 
effects associated with different placebo interventions can 
vary considerably. Some of this evidence comes from the Co-
chrane review which found that not only the type of placebo is 
an effect modifier, but also the information given to patients 
(trials not fully disclosing placebo use reported larger effects) 
or the purpose of the trial (trials explicitly investigating pla-
cebo effects reported larger effects). There is also some evi-
dence from trials which directly compared different types of 
placebo [3, 5]. Several systematic reviews indicate that factors 
like the dosage, the way of application or the number of phy-
sician contacts have an influence on response rates in placebo 
groups [34–36]. Findings from basic research strongly suggest 
that the specific context of an intervention has a major impact 
on the response to a (true or sham) intervention [37]. In the 
case of sham acupuncture direct physiological interventions 
associated with at least some sham interventions also might 
play an important role. In the light of this evidence it seems at 
least plausible that sham acupuncture interventions may often 
but – as it seems from the data – not always be associated with 
considerable effects. On average, these effects might be larger 
than those associated with pharmacological and other physi-
cal placebos.
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moderate for both subgroups of trials with I2 being 49% and 
38%, respectively. According to Hrobjartsson and Gøtzsche, 
a series of 4 recent large acupuncture trials from Germany 
had considerable impact on the overall estimate. When these 
4 trials [i.e. 12, 21, 23, 28] contributing to the analysis of con-
tinuous outcomes were excluded, the pooled effect estimate 
was reduced to –0.30 (95% CI –0.46, –0.13) and no longer dif-
fered significantly from that for non-acupuncture studies.
When we analyzed separately the different categories of 
‘physical placebos’ other than sham acupuncture, SMDs be-
tween subgroups differed significantly (test for subgroup dif-
ferences Chi2 = 12.90, p = 0.01; see table 2). The pooled SMD 
over no-treatment controls for placebos for electrotherapy, 
ultrasound or a physiotherapeutic intervention was slightly 
larger (–0.52) than for sham acupuncture (p = 0.44). The 
pooled random-effects relative risk (of a negative outcome) of 
the 5 studies which reported a dichotomous outcome measure 
for the comparison between the sham and the no-treatment 
group was 0.86 (95% CI 0.67, 1.11) for acupuncture studies 
and 0.94 (95% CI 0.89, 1.00) for other studies, confirming a 
larger effect of sham acupuncture (p value for differences be-
tween subgroups based on fixed-effects analyses = 0.001). 
When the recent large German trial [33] was excluded from 
this analysis, the difference was non-significant.
Discussion
In our re-analysis of data from the Cochrane review by Hrob-
jartsson and Gøtzsche on placebo interventions for all kinds 
of conditions [8] sham acupuncture interventions were, on av-
erage, associated with larger effects over no-treatment control 
groups than were other ‘physical placebos.’ However, if the 
group of other ‘physical placebos’ was further subdivided 
there were also significant differences between subgroups. 
Our results have to be interpreted with great caution. They 
are based on a re-analysis of a subgroup analysis from Hrob-
jartsson and Gøtzsche [8] with an indirect comparison of acu-
puncture and other trials. The trials included form an ex-
tremely heterogeneous sample and factors other than the 
sham interventions might have differed between the groups of 
trials compared. For example, it seems likely that effects of 
sham interventions vary between different conditions. Com-
parisons of sham acupuncture or other physical placebos and 
no-treatment groups cannot be blinded and many studies 
have measured subjective patient-rated endpoints. Further-
more, the extent of co-interventions in both sham or placebo 
trials using sham acupuncture and –0.26 (95% CI –0.37, –0.15) 
for other studies with ‘physical placebos’ (test for subgroup 
differences Chi2 = 7.37, p = 0.007; fig. 1). Heterogeneity was 
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